|
|
|
|
|
First-Line Treatment of Metastatic NSCLC
|
|
|
Monday, March 13, 2022 • 7:15 PM ET
|
|
|
|
Hossein Borghaei, DO, MS
Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Co-Director, Immune Monitoring Facility
Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, PA
|
|
|
|
|
|
Prof. Dr. Martin Reck
Head of Department Thoracic Oncology
Head of Clinical Trial Department
LungenClinic Grosshansdorf
Germany
|
|
|
|
|
Objectives:
Gain insights into factors guiding treatment selection in non-small cell lung cancer (NSCLC) lacking actionable genetic alterations Review safety and efficacy data of immune checkpoint inhibitors in first-line treatment of metastatic NSCLC Discuss treatment decision-making based on PD-L1 expression levels in NSCLC
Register Now
|
|
|
|
|
|
|
|
